B. Riley Securities Reiterates Buy on Starling Oncology, Lowers Price Target to $10
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsReiterationPrice Target
B. Riley Securities analyst Yuan Zhi reiterates Starling Oncology (NASDAQ:STLN) with a Buy and lowers the price target from $11 to $10.
B. Riley Securities analyst Yuan Zhi reiterates Starling Oncology (NASDAQ:STLN) with a Buy and lowers the price target from $11 to $10.